We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Specialized Nuclear Bodies Delay and Promote Repair of DNA Damage

By LabMedica International staff writers
Posted on 14 Mar 2019
A molecular mechanism that helps minimize the impact of natural DNA errors, which occur during the process of cell division and replication, was identified and characterized in cultures of human cells.

Failure to complete DNA replication is a by-product of genome doubling in almost every cell cycle. More...
During mitosis, under-replicated DNA (UR-DNA) is converted into DNA lesions, which are inherited by daughter cells and sequestered in 53BP1 nuclear bodies (53BP1-NBs).

The fate of DNA with unresolved replication intermediates is not known. Previous studies showed that mild replication stress increased the frequency of chromosomal lesions that were transmitted to daughter cells. Throughout G1, these lesions were sequestered in nuclear compartments marked by p53-binding protein 1 (53BP1) and other chromatin-associated genome caretakers. The number of such 53BP1 nuclear bodies increased after genetic ablation of BLM, a DNA helicase associated with dissolution of entangled DNA. Conversely, 53BP1 nuclear bodies were partially suppressed by knocking down SMC2, a condensin subunit required for mechanical stability of mitotic chromosomes. In addition, 53BP1 nuclear bodies protected chromosomal fragile sites sequestered in these compartments against erosion.

In the current study, which was published in the February 25, 2019, online edition of the journal Nature Cell Biology, investigators at the University of Copenhagen (Denmark) showed that the formation of 53BP1-NBs interrupted the chain of repetitive damage intrinsically embedded in UR-DNA. This result was obtained by labeling 53BP1-NBs in living human cells using fluorescent dyes and then following them under a microscope over several successive generations. Using this method, the investigators traced the fate of inherited DNA damage directly from the time of generation in mother cells to their final destiny in daughter cells.

The investigators found that unlike clastogen-induced 53BP1 foci that were repaired throughout interphase, 53BP1-NBs restrained replication of the embedded genomic loci until late S phase, thus enabling the dedicated RAD52-mediated repair of UR-DNA lesions. A clastogen is a mutagenic agent giving rise to or inducing disruption or breakages of chromosomes, leading to sections of the chromosome being deleted, added, or rearranged. RAD52 is a protein that plays a central role in genetic recombination and DNA repair by promoting the annealing of complementary single-stranded DNA and by stimulation of the RAD51 recombinase.

The absence or malfunction of 53BP1-NBs caused premature replication of the affected loci, accompanied by genotoxic RAD51-mediated recombination (a genotoxic agent is a chemical or another agent that damages cellular DNA, resulting in mutations or cancer). Thus, by adjusting replication timing and repair pathway choice at under-replicated loci, 53BP1-NBs enabled the completion of genome duplication of inherited UR-DNA and prevented the conversion of under-replications into genome instability.

"53BP1 nuclear bodies delay cell division in daughter cells in order to reach the only remaining time in their lifecycle when they can mend DNA lesions that their mother caused but could not fix. This second chance is vital because it is also the last one. We have predicted and then experimentally documented that a failure of this second chance converts the initially curable DNA damage to one that can no longer be fixed. Accumulation of such mishaps could lead to disease, including cancer", said senior author Dr. Kai John Neelsen, assistant professor of protein research at the University of Copenhagen.

Related Links:
University of Copenhagen


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.